BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

06/26/2026

BriaCell has entered a Memorandum of Understanding with Uneedle to support the potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration.

Technology is currently used in BriaCell’s pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the patient and provider experience.

Read more from Jeroen Wissink, CEO of Uneedle: https://bit.ly/4eD6tw5

06/25/2026

“Uneedle’s microneedle technology is already being used in our pivotal Phase 3 study, and we believe this approach may support faster, more convenient administration and a more patient-friendly treatment experience,"" noted William V. Williams, MD, BriaCell's President & CEO. Learn more: https://bit.ly/4eD6tw5

06/25/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) has entered into a Memorandum of Understanding (“MoU”), with Uneedle, a microneedle based drug-delivery device company in the Netherlands, to support the continued use and commercial readiness of Uneedle’s proprietary microneedle technology for intradermal administration of BriaCell’s lead Phase 3 clinical candidate, Bria-IMT, for the treatment of metastatic breast cancer. For more information, visit: https://bit.ly/4eD6tw5

We’re Hiring at Briacell Therapeutics!BriaCell is on a mission to transform cancer therapy, and we need talented individ...
06/18/2026

We’re Hiring at Briacell Therapeutics!

BriaCell is on a mission to transform cancer therapy, and we need talented individuals who are excited to help shape the future of biotech. Come work alongside a dedicated team where your ideas and impact truly matter.

See our open roles here: https://bit.ly/478ecPX

Join the BriaCell Team!Briacell Therapeutics is expanding, and we’re looking for enthusiastic, driven professionals read...
06/17/2026

Join the BriaCell Team!

Briacell Therapeutics is expanding, and we’re looking for enthusiastic, driven professionals ready to make a difference in cancer treatment. If you’re passionate about biotech innovation and thrive in a collaborative environment, we want to hear from you!

Explore our current opportunities here: https://bit.ly/478ecPX

BriaCell is hiring!Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us...
06/09/2026

BriaCell is hiring!

Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us in advancing innovative cancer treatments. If you’re ready to make a meaningful impact in biotech and work alongside a dedicated team, we’d love to hear from you.

Explore our open roles and take the next step in your career today. https://bit.ly/478ecPX

06/02/2026

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program, comments on the encouraging clinical findings from BriaCell's ongoing pivotal Phase 3 study which showed clinically meaningful benefit in heavily pre-treated metastatic breast cancer patients. Learn more: https://bit.ly/4ejBfu3

06/02/2026

Final Phase 2 data from BriaCell's Bria-IMT study, presented at , show 55% >1-year and 27% >2-year survival in heavily pre-treated metastatic breast cancer patients treated with the same Bria-IMT formulation as the Phase 3 study. There were no treatment-related discontinuations and no unexpected safety signals. Learn more: https://bit.ly/4ejBfu3

06/01/2026

Saranya Chumsri, MD, principal investigator in the Phase 3 study of Bria-IMT+CPI and Professor of Oncology at Mayo Clinic Florida, comments on positive Phase 2 clinical data presented at , including median overall survival rates as high as 16.6 months and a high rate of long-term survival in heavily pre-treated metastatic breast cancer patients. Learn more: https://bit.ly/4ejBfu3

06/01/2026

"We are increasingly optimistic with the early quality of life and biomarker data from our ongoing pivotal Phase 3 Bria-ABC trial demonstrating sustained clinical activity in patients with advanced MBC who did not respond to multiple prior treatments,"" noted William V. Williams, MD, BriaCell's President & CEO. Learn more: https://bit.ly/4ejBfu3

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Category